%0 Journal Article
%A Oubari, Sara
%A Papathanasiou, Maria
%A Michel, Lars
%A Rassaf, Tienush
%A Thimm, Andreas
%A Hagenacker, Tim
%A Ehling, Daniela
%A Wieczorek, Stefan
%A Naser, Eyad
%A Hegenbart, Ute
%A Schönland, Stefan
%A Dührsen, Ulrich
%A Reinhardt, Hans Christian
%A Carpinteiro, Alexander
%T Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival.
%J Annals of hematology
%V 104
%N 3
%@ 0939-5555
%C New York
%I Springer
%M DKFZ-2025-00604
%P 1777-1788
%D 2025
%Z 2025 Mar;104(3):1777-1788
%X Systemic light-chain amyloidosis (AL) is an acquired protein misfolding disease characterized by deposition of immunoglobulin light-chain fibrils most often secreted from clonal plasma cells. In this retrospective study we analyzed the impact of iFISH aberrations on clinical characteristics and outcomes in 175 AL patients presented between 2015 and 2024. The most common aberrations were t(11;14) (57
%K +1q21 (Other)
%K AL amyloidosis (Other)
%K IFISH (Other)
%K Mayo stage (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40119178
%R 10.1007/s00277-025-06256-7
%U https://inrepo02.dkfz.de/record/300104